Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Operating Leases (Tables)

Operating Leases (Tables)

6 Months Ended

Jun. 30, 2019

The following table shows the lease costs for the three and six months ended June 30, 2019 (in thousands):


	Three months ended		Six months ended
	June 30,		June 30,
	2019		2019
Lease cost:
Operating lease cost	$	1,024	$	2,014
Short-term lease cost		121		168
	$	1,145	$	2,182

			Six months ended
			June 30,
			2019
Other information:
Operating cash flows from operating leases (in thousands)			$	2,194

			June 30,
			2019

Weighted-average remaining lease term - operating leases			7.8 years
Weighted-average discount rate - operating leases			7.2%

Schedule of maturities of operating lease liabilities

The maturities of operating lease liabilities are as follows (in thousands):


	Operating leases

2019	$	2,037
2020		4,110
2021		4,153
2022		4,158
2023		3,918
after 2023		16,302
Total lease payments		34,678
Less: Imputed interest		(8,674)
Present value of lease liability	$	26,004

The Company has operating leases in relation to property for office and research facilities. The maximum lease term without activation of termination options is to 2041.